Nascent Biotech Inc
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing Multi… Read more
Nascent Biotech Inc (NBIO) - Net Assets
Latest net assets as of June 2024: $-514.54K USD
Based on the latest financial reports, Nascent Biotech Inc (NBIO) has net assets worth $-514.54K USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($227.39K) and total liabilities ($741.93K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-514.54K |
| % of Total Assets | -226.28% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Nascent Biotech Inc - Net Assets Trend (2014–2024)
This chart illustrates how Nascent Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nascent Biotech Inc (2014–2024)
The table below shows the annual net assets of Nascent Biotech Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-03-31 | $-256.67K | +80.20% |
| 2023-03-31 | $-1.30 Million | -93.03% |
| 2022-03-31 | $-671.48K | -42.11% |
| 2021-03-31 | $-472.50K | +83.57% |
| 2020-03-31 | $-2.88 Million | -496.42% |
| 2019-03-31 | $-482.16K | -458.20% |
| 2018-03-31 | $-86.38K | -111.77% |
| 2017-03-31 | $733.76K | +146.77% |
| 2016-03-31 | $-1.57 Million | +28.92% |
| 2015-03-31 | $-2.21 Million | -52.19% |
| 2014-03-31 | $-1.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nascent Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2018109900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $24.00 Million | % |
| Total Equity | $-256.67K | 100.00% |
Nascent Biotech Inc Competitors by Market Cap
The table below lists competitors of Nascent Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Financial 15 Split Corp
PINK:FNNCF
|
$51.72K |
|
Boratr Co. Ltd.
KO:250000
|
$51.72K |
|
Feel Foods Ltd
PINK:FLLLF
|
$51.77K |
|
ALUP11F
SA:ALUP11F
|
$51.90K |
|
VERASTEM (2VS.SG)
STU:2VS
|
$51.65K |
|
Big Tech 50 R&D-Limited Partnership
TA:BIGT
|
$51.60K |
|
Misr Beni Suef Cement
EGX:MBSC
|
$51.59K |
|
Arogo Capital Acquisition Corp. Warrant
NASDAQ:AOGOW
|
$51.59K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nascent Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,296,137 to -256,674, a change of 1,039,463.
- Net loss of 2,087,682 reduced equity.
- New share issuances of 1,561,000 increased equity.
- Other factors increased equity by 1,566,145.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.09 Million | -813.36% |
| Share Issuances | $1.56 Million | +608.16% |
| Other Changes | $1.57 Million | +610.17% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Nascent Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-03-31 | $0.00 | $0.01 | x |
| 2017-03-31 | $0.00 | $0.01 | x |
| 2018-03-31 | $0.00 | $0.01 | x |
| 2019-03-31 | $-0.01 | $0.01 | x |
| 2020-03-31 | $-0.06 | $0.01 | x |
| 2021-03-31 | $0.00 | $0.01 | x |
| 2022-03-31 | $-0.01 | $0.01 | x |
| 2023-03-31 | $-0.01 | $0.01 | x |
| 2024-03-31 | $0.00 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nascent Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (14.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.77 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.93 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.99 Million |
| 2017 | 154.95% | 37.90% | 3.33x | 1.23x | $1.06 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.21 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.32 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.72 Million |
| 2021 | 0.00% | -127.84% | 1.00x | 0.00x | $-911.52K |
| 2022 | 0.00% | -47.04% | 9.49x | 0.00x | $-403.24K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.67 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.06 Million |
Industry Comparison
This section compares Nascent Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nascent Biotech Inc (NBIO) | $-514.54K | 0.00% | N/A | $51.66K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |